cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Fibrogen Inc
11 own
10 watching
Current Price
$0
$-0.29
(-1.6%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,717.96M
52-Week High
52-Week High
25.69
52-Week Low
52-Week Low
8.67
Average Volume
Average Volume
0.07M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,717.96M
icon52-Week High25.69
icon52-Week Low8.67
iconAverage Volume0.07M
iconDividend Yield--
iconP/E Ratio--
What does the Fibrogen Inc do?
FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Read More
How much money does Fibrogen Inc make?
News & Events about Fibrogen Inc.
Globe Newswire
1month ago
Study Did Not Meet Primary EndpointSAN FRANCISCO, May 05, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc.(NASDAQ: FGEN) today announced that MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with transfusion-dependent lower risk myelodysplastic syndromes (MDS) did not ...
PR Newswire
1month ago
Bassem Elmankabadi, M.D. joins Foresee Pharmaceuticals as a Senior Vice President of Clinical Development Bassem Elmankabadi, M.D. joins Foresee Pharmaceuticals as a Senior Vice President of Clinical Development PR Newswire TAIPEI, April 17, 2023 TAIPEI, April 17, 2023 /PRNewswire/ -- Foresee...
Globe Newswire
3 months ago
SAN FRANCISCO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Mark Eisner, M.D., M.P.H., Chief Medical Officer, will participate in a panel discussion at Cowens 43rd Annual Health Care Conference to be held in Boston on March 5 - 8, 2023. Details of the ...
Globe Newswire
3 months ago
SAN FRANCISCO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2022 financial results on Monday, February 27 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment ...
Frequently Asked Questions
Frequently Asked Questions
What is Fibrogen Inc share price today?
plus_minus_icon
Can Indians buy Fibrogen Inc shares?
plus_minus_icon
How can I buy Fibrogen Inc shares from India?
plus_minus_icon
Can Fractional shares of Fibrogen Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Fibrogen Inc stocks?
plus_minus_icon
What is today’s traded volume of Fibrogen Inc?
plus_minus_icon
What is today’s market capitalisation of Fibrogen Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Fibrogen Inc?
plus_minus_icon
What percentage is Fibrogen Inc down from its 52-Week High?
plus_minus_icon
What percentage is Fibrogen Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.29
(-1.6%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
$127.81
$1.90 (1.51 %)
Galapagos NV
Galapagos NV
$42.95
$0.06 (0.14 %)
Ocular Therapeutix Inc
Ocular Therapeutix Inc
$7.66
$0.05 (0.66 %)
Xencor Inc
Xencor Inc
$27.14
$-0.11 (-0.40 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
$127.81
$1.90 (1.51 %)
Galapagos NV
Galapagos NV
$42.95
$0.06 (0.14 %)
Ocular Therapeutix Inc
Ocular Therapeutix Inc
$7.66
$0.05 (0.66 %)
Xencor Inc
Xencor Inc
$27.14
$-0.11 (-0.40 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00